
⸺ Synova Research
GHRH analogue studied for stimulation of growth hormone release, with research interest in visceral fat, body composition and metabolic markers.
Website checkout coming soon — for now, orders are placed directly via our Telegram. Fast replies & secure payment links.
Independently tested
COA on request
Next-day UK dispatch
Order before 2pm
Research use only
Not for human consumption
⸺ Important
⸺ Overview
Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH). Researchers investigate its ability to stimulate endogenous growth hormone release from the pituitary and its downstream effects on fat metabolism, lean tissue preservation and metabolic profile.
⸺ Mechanism of Action
Tesamorelin binds the GHRH receptor on pituitary somatotrophs, increasing pulsatile growth hormone release. The resulting rise in IGF-1 is studied for its influence on lipolysis (particularly visceral adipose tissue), protein synthesis and insulin-sensitivity markers in animal models.
⸺ Research
Studies report reductions in visceral adipose tissue following sustained Tesamorelin exposure in animal subjects.
Research consistently shows increased pulsatile GH release and elevated IGF-1, supporting use as a tool compound for GHRH-axis studies.
Preclinical work has examined effects on lipid profiles and glucose regulation under chronic administration.
Summarised from preclinical literature for informational purposes only. Not medical or veterinary advice. Synova Research products are sold strictly for in-vitro and laboratory research.
⸺ Details

Investigational triple receptor agonist targeting GLP-1, GIP and glucagon — studied in animal models for appetite control, energy expenditure and glucose balance.

Dual GLP-1 and GIP receptor agonist studied in preclinical models for glucose regulation, insulin sensitivity and energy balance.

Synthetic analogue of the GLP-1 hormone used in research to study glucose regulation, insulin secretion and the incretin response.